Kornimate/medical-research-clean huggingface dataset:
characteristics of trachomatous corneal opacity in fayoum university hospital

Conditions: Corneal Opacity

Summary: the purpose of this study is to assess the characteristics of trachomatous corneal opacity in patients with signs of trachoma using anterior segment optic coherence tomography and pentacam

after approval of the local institutional ethics committee and local institutional review board, patient presented to fayoum university hospital was examined for corneal opacity with signs of trachoma after a detailed informed consent was signed by eligible patients and investigated by anterior segment optic coherence tomography and pentacam. descriptive statistics were presented in the form of mean and standard deviation for numerical variables while numbers and percentages are used for the categorical variables. paired samples t-test was used to study anterior segment optic coherence tomography and pentacam in evaluating corneal thickness. bland-altman plot was used to study the agreement between the two methods ibm spss version 28 for windows software was used for the analysis and stata 16 was used for the bland-altman plot. a p-value of \< 0.05 was considered significant.

Eligibility criteria:
inclusion criteria: * patients with corneal opacity accompanied by signs of trachoma exclusion criteria: * corneal opacity due other causes * history of corneal surgery
immersive virtual reality for stroke motor rehabilitation

Conditions: Chronic Stroke; Motor Disorders

Summary: the present study aims at investigating (i) the feasibility in chronic stroke of using a dedicated virtual reality (vr) based system that embeds real-time 3d motion capture and embodied visual feedback to deliver functional exercises designed for training of impaired upper limb motor skills, (ii) whether chronic stroke survivors improve in functional outcomes in the upper limb when exposed to intensive vr-based therapy, and (iii) safety and tolerance to such a technology. the investigators hypothesize that intensive vr-based rehabilitation may lead to high rehabilitation doses and functional improvement in chronic stroke.


Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic minor-to-moderate (0\<nihss\<16) stroke with hemiparesis and experiencing arm motor difficulties * at least 6 months after stroke incident * maximum 4 on the medical research council scale (mrcs) for shoulder elevation and elbow flexion/extension * 18 years and older * first ever stroke exclusion criteria: * participating in another movement treatment study at the time of the present study * severe cognitive impairment (mini mental status examination score \< 18 points) * orthopedic impairment or visual disorders limiting the treatment * unable to give informed consent form * risk of epileptic seizures

Keywords: stroke neurorehabilitation virtual reality rehabilitation dose motor rehabilitation
retinal function in diabetic patients without retinopathy

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: the primary purpose was to assess, in diabetic patients without diabetic retinopathy and control subjects, color vision, contrast sensitivity, electroretinography, and flicker-induced vasodilatation using the dynamic vessel analyzer, in order to specify the earliest impaired retinal cells in diabetes, and gain more insight into diabetic retinopathy pathogenesis.

type 1 and type 2 diabetic patients with no diabetic retinopathy and no hypertension were compared with sex and age-matched control subjects. color vision was tested with the desaturated lanthony 15-hue test. contrast sensitivity was assessed with the pelli-robson contrast sensitivity test. pattern-electroretinogram, ganzfeld full-field electroretinogram and multifocal electroretinogram were recorded according to the international society for clinical electrophysiology of vision (iscev). flicker-induced vasodilatation in retinal arteries and veins was assessed using the dynamic vessel analyzer.

Eligibility criteria:
inclusion criteria: * for diabetic patients : * age between 20 and 55 * type 1 or type 2 diabetes mellitus * diabetes duration of more than 5 years * no diabetic retinopathy on fundus examination or fundus photographs * for control subjects : * sex and age matching with the diabetic patients * no diabetes, no familial or personal history of elevated blood sugar exclusion criteria: \*for both diabetic patients and control subjects : * presence of cataract or history of cataract surgery * intraocular pressure of more than 21 mmhg * abnormal score on the ishihara test * other ocular disease * ametropia more than 3 diopters, anisometropia more than 1 diopter, astigmatism more than 1 diopter * systemic hypertension (defined as systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg) * treatment with vasoactive drugs * tobacco consumption of more than 20 cigarettes a day

Keywords: diabetic retinopathy color vision contrast sensitivity electroretinogram flicker-induced vasodilatation dynamic vessel analyzer
the aim of this research is to better understand how complete spinal cord injury may change erogenous zones in adult males

Conditions: Spinal Cord Injury; Spinal Cord Injury No Sensory/Motor in S4-S5

Summary: a complete spinal cord injury (sci) in men is characterized by the total loss of motor skills and sensations below the injury. the loss of penile sensation, the erogenous zone primarily involved in sexual response, is involved in sexual dysfunction, impacting sexual pleasure and quality of life. the management of genito-sexual dysfunction is a priority for paraplegic patients, ahead of bladder-sphincter and motor functions. for tetraplegic patients, the restoration of genito-sexual functions is their second priority after the upper limb motor skills recovery (anderson, 2004)(anderson et al., 2007). medical assistance is currently available to i) restore erectile function allowing penetrative sexual intercourse, ii) enable sperm collection for reproductive purposes, iii) assisted reproductive techniques which allowing most often these patients to achieve their fatherhood goals (giuliano et al., 2019)(chochina et al., 2016)(lombardi et al., 2015). nevertheless, the assessment and management of the loss of genital sensations have been poorly studied, alike sexual pleasure and satisfaction in sci patients (philpott et al., 2006). erogenous zones are regions of the body that elicit sexual pleasure and trigger or enhance sexual arousal when appropriately stimulated. the discovery of other forms of physical intimacy that move away from the traditional scripts of phallo-centric male sexuality (earle et al., 2020)(giurleo et al., 2022)(ostrander, 2009)(burns et al., 2008) could improve sexual pleasure. the stimulation of hypersensitive regions in the skin areas corresponding to the lesion level and above has the potential to represent one of the strategies to compensate the lack of sensitivity of the genital-sexual organs (hohmann, 1972)(bach-y-rita, 1999)(elliott, 2002)(anderson et al., 2007)(lopez et al., 2008)(alexander \& marson, 2018). but again, these data are scares and limited to few testimonials. the aim of the present research program is to identify, define and characterize erogenous zones in men with complete sci in the absence of sensitivity of the genitals. the study design is a qualitative observational study, and the consolidated criteria for reporting qualitative research (coreq) will be followed (tong et al., 2007). a minimum of fourteen semi-structured interviews with men with a complete sci followed in a neuro-urology department will be conducted with the recruitment stopped once data saturation is achieved.


Eligibility criteria:
inclusion criteria: * men * complete spinal cord injury * heterosexual * sexual activity prior to the injury exclusion criteria: * syringomyelia * other neurological condition * no sexual activity since the injury

Keywords: sexuality erogenous zones men semi-structured interviews
laparoscopic tactile imaging in urogynecologic surgery

Conditions: Pelvic Floor Disorders

Summary: during laparoscopic surgery, video camera becomes a surgeon's eyes since the surgeon uses image from the video camera positioned inside the patient's body to perform the procedure. the greatest limitation is the impairment or complete lack of tactile sensation normally used to assist in surgical dissection and decision making. the investigator proposes to develop a tactile sensing system, laparoscopic tactile imager (lti), to be used in urogynecological laparoscopic surgery for tactile imaging and tissue characterization (elasticity, structure, boundaries, blood vessel detection) which will be imposed on the video image at area of interest in real time.

for this study, the investigator identified the sacrocolpopexy as the target procedure for the evaluation of lti. in the cases of sacrocolpopexy, often performed in conjunction with a hysterectomy, one of the most frustrating elements is the lack of tactile feedback at the level of the sacral promontory. the surgeon needs to open up the peritoneum and dissect the underlying tissue to expose the sacral bony structures and ligament without injury to the surrounding bowel, ureter or vascular structures. sometimes, the sacral promontory is covered with a fat pad which makes it difficult to visualize the promontory and the "safe" space below the aorta and between the iliac arteries/veins is difficult to discern. a difference that is very easy to appreciate with an open procedure where one can easily palpate through the fatty tissues. that step is very critical for the repair and has the greatest potential for catastrophic error without tactile sensation. because of the reproducibility of the surgical technique and target anatomy for this portion of the procedure, it was thought the sacral promontory dissection to identify and clear the anterior longitudinal ligament would be appropriate surgical procedure to evaluate the use of lti.

Eligibility criteria:
inclusion criteria: 1. stage 2 or greater pelvic organ prolapse; 2. scheduled pelvic floor surgery. exclusion criteria: 1. active cancer of the colon, rectum wall, cervix, vaginal, uterus or bladder; 2. ongoing or prior radiation therapy for abdominal or pelvic cancer; 3. recent (less than four months) pelvic surgery; 4. surgically absent rectum or bladder; 5. significant circulatory or cardiac conditions that could cause excessive risk from the examination as determined by attending physician; 6. severe abdominal or pelvic adhesions preventing access to pertinent anatomy; 7. known or suspected bleeding disorder.
bivolutx: bicuspid aortic stenosis with evolut platform international experience.

Conditions: Bicuspid Aortic Valve

Summary: prospective non interventional, observational registry of 150 patients undergoing tavi with evolut platform for bicuspid aortic stenosis.

study design study design: prospective non-interventional multicenter registry screening: msct submitted to core lab \& sizing strategy pre-declared (annular sizing, supra-annular sizing, mix of both methods) follow up: msct and tte to cooper lab tavi treatment predilatation according to aortic annulus dmin evolut pro (23-26-29) and evolut r 34 xl annular anchoring of the thv postdilatation according to the operators' discretion study population all consecutive patients presenting with severe and symptomatic bicuspid aortic valve stenosis or mixed disease inclusion criteria 1. age ≥18 years. 2. nyha≥2 and/or syncope and/or angina. 3. patient judged by the heart team as indicated for tavi. 4. anatomical suitability for transfemoral-tavi with evolut pro or evolut r xl, based on msct assessment. 5. estimated life-expectancy\>1 year. exclusion criteria 1. age \<18 years 2. asymptomatic patients 3. estimated life expectancy\<1 year 4. pure aortic regurgitation. 5. lvef\<20% 6. no baseline msct evaluation. 7. unsuitable aortic root anatomy for evolut pro or xl. 8. unsuitable peripheral vasculature for transfemoral evolut pro or xl. primary endpoint valve performane secondary endpoints 30 day and 1 year mortality patient-prosthesis mismatch ellipticity index at 30 days follow-up 30 days: physical examination, ecg, tte /msct upon operators' judgement 1 year: physical examination, ecg, tte.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. nyha≥2 and/or syncope and/or angina. 3. patient judged by the heart team as indicated for tavi. 4. anatomical suitability for transfemoral-tavi with evolut pro or evolut r xl, based on msct assessment. 5. estimated life-expectancy\>1 year. exclusion criteria: 1. age \<18 years 2. asymptomatic patients 3. estimated life expectancy\<1 year 4. pure aortic regurgitation. 5. lvef\<20% 6. no baseline msct evaluation. 7. unsuitable aortic root anatomy for evolut pro or xl. 8. unsuitable peripheral vasculature for transfemoral evolut pro or xl.

Keywords: bicuspid tavi tavr self-expanding evolut
imiquimod for preventing keloid recurrence

Conditions: Keloid

Summary: this is an open-label, single-arm, pilot study on the effects of topical imiquimod treatment in preventing keloid recurrence after surgical excision. keloids are abnormal scars that form in certain genetically predisposed individuals following trauma to the skin. they can be physically disabling and cause social impairment. many therapies have been proposed and trialed for the permanent removal of keloids, but they all have limited efficacy. topical imiquimod therapy has been reported to decrease keloid recurrence following keloidectomy in human patients. given all previous reports of adjuvant imiquimod therapy to keloidectomy initiated imiquimod therapy after keloidectomy, the investigators would like to test the efficacy of topical imiquimod pre-treatment in preventing keloid recurrence after surgical excision. therefore, the investigators are initiating an open-label pilot study of 10 patients age 18 or greater with keloids on the trunk and extremities excluding the groin and hands and feet who present to the dermatology clinic for standard of care keloid excision. key exclusion criteria include vulnerable populations, immunocompromised state, hypersensitivity to study drug components, and keloids outside of specified areas. the main study intervention will be 6 weeks of treatment with topical 5% imiquimod cream, starting 1 week prior to surgical excision.


Eligibility criteria:
inclusion criteria: * age 18 or greater * men and women who present clinically with keloids requesting excision * any number of keloids * keloid no larger than 5cm in diameter at the base * clinical findings consistent with keloid formation * location of keloid in low-risk areas - areas other than above the neck, hands, feet, or groin * able and willing to give informed consent exclusion criteria: * age \< 18 * hypersensitivity to imiquimod or to any of the excipients (methylhydroxybenzoate, propylhydroxybenzoate, cetyl alcohol, and stearyl alcohol) * involvement in a trial of another experimental intervention within 30 days * life threatening disease * use of immunosuppressive medications such as oral corticosteroids * bleeding disorders * not available for follow-up for 10 weeks * pregnant, intention to become pregnant during treatment phase of trial, or breastfeeding
assessment of the response to the complete vaccination guidelines against sars-cov2

Conditions: COVID-19

Summary: prospective observational single-center study in which the impact of anti-tnf biological treatment on the humoral response after complete vaccination against sars-cov2 in patients with inflammatory bowel disease is analyzed.

prospective observational single-center study in which the impact of anti-tnf biological treatment on the humoral response after complete vaccination against sars-cov2 in patients with inflammatory bowel disease is analyzed. the first objective is to compare the seroconversion rate after full vaccination against sars-cov2 in patients with ibd treated with anti-tnf drugs versus patients treated with ustekinumab / vedolizumab and patients without immunosuppressive treatment. the patients included in the study belong to the health area of the virgen macarena university hospital who meet the following inclusion criteria and none for exclusion.

Eligibility criteria:
inclusion criteria: * be of legal age (\> 18 years). * diagnosis of inflammatory bowel disease (crohn's disease or ulcerative colitis). * complete vaccination schedule (one or two doses depending on previous sars-cov2 infection) between one and four months prior to the determination of anti-sars-cov2 antibodies. * treatment with biological therapy for at least 6 weeks prior to the time of vaccination for the group of patients treated with biological drugs. exclusion criteria: * last vaccination dose more than four months ago from the determination of antibodies against sars-cov2.
association of bisphenol a,paraben exposure and type 2 diabetes

Conditions: Type2 Diabetes; Bisphenol A

Summary: the aim of this study is to evaluate the association between bpa , paraben levels and type 2 dm patients

the first phase of the study will include a questionnaire : * the cases and control will be asked about demographic information such as residence, age, education, and occupation. * history of discovery of diabetes. * exposure to products and materials such as polycarbonate plastics, cosmetics and beverages containing bisphenol a and paraben and it will be evaluated through exposure sheet through asking about dietary exposure, environmental exposure and medical exposure. then clinical evaluation including: * full clinical examination will be performed for cases and control. * anthropological data: their weights, heights and waist circumference will be measured. the body mass index (bmi) will be calculated by weight (kg)/height (m)2 formula. * investigations: routine and specific investigation as blood glucose level, hba1c and lipid profile. * urine specimens will be collected in clean, glass containers will labeled with the subject identification number. turbid sample or those containing blood will be excluded. * all specimens will be stored frozen below 20 degree centigrade. * urine samples will be analyzed by high performance liquid chromatograph (hplc) to detect bispenol a and parabens levels.

Eligibility criteria:
inclusion criteria: 1. adult patients ( 18 y or elder). 2. type 2 dm exclusion criteria: * type 1 dm * less than 18 y * history of chronic diseases such as liver failure, cardiac patients......etc
non inferiority trial of standard rt versus hypofractionated split course in elderly vulnerable patients with hnscc

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: randomized comparison between standard radiotherapy and hypofractionated split course schedule. compared to standard radiotherapy, the investigators expect that hypofractionated split course (interruption of 2 weeks) radiotherapy will improve compliance to treatment, acute tolerance of treatment, preservation of autonomy, prevention of malnutrition, with the same efficacy, measured by the locoregional control rate.


Eligibility criteria:
inclusion criteria: * patients aged 70 or over * siog group 2 (vulnerable) * life expectancy \> 12 weeks * ps \< 2 * histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, cervical nodes (unknown primary). * first line treatment * at least one measurable lesion (recist) * stage ii to iv * patients unsuitable for surgery of the primary tumour: non resectable tumor, anesthesia contra indication, patient's refusal, or organ sparing approach. cervical nodes dissection authorized * patients planned to be treated in a curative intent with radiotherapy alone on primary tumor site and on at least one head and neck node area * consent form signed exclusion criteria: * primary squamous cell carcinoma of sinus, the skin or of the salivary glands * stage i cancer * radiotherapy planned on primary tumor only, or on neck nodes only. for patients with metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma, patients will be excluded if head and neck mucosa (oropharynx, larynx, hypopharynx) is not included as a target volume for radiotherapy * prior radiotherapy of head and neck area * concurrent chemotherapy or immunotherapy or hormonotherapy * induction chemotherapy * concomitant infection requiring iv antibiotics * cancer other than head and neck cancer within the previous 5 years (baso cellular skin carcinoma and cervix carcinoma excepted) * conditions that could lead to bad compliance

Keywords: hnscc elderly geriatry
postoperative pain after a laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: randomized controlled trial to compare the effect of low (8 mmhg) versus standard (14 mmhg) insufflation pressure of co2 pneumoperitoneum on postoperative pain in patients undergoing laparoscopic cholecystectomy


Eligibility criteria:
inclusion criteria: * asa 1 or asa 2 * uncomplicated symptomatic gallblader lithiasis scheduled for elective surgery * no choledocholithiasis * no associated surgical procedures * no cerebrovasculare accident with neurological sequelae or other neurological disorders that affects sensation of pain * no ascites * no carcinomatosis exclusion criteria: * conversion to laparotomy * need to keep an escat drain
study of da+ldd in the treatment of femoropopliteal occlusive disease

Conditions: Peripheral Artery Disease; Endovascular Treatment

Summary: this study will evaluate the effectiveness and safety of directional atherectomy plus local drug delivery using balloon catheter system in the treatment of femoropopliteal occlusive disease. patients of femoropopliteal occlusive disease will randomly receive directional atherectomy plus local drug delivery using balloon catheter system and dilation using drug-coated balloon. their clinical outcomes (e.g. 12-month late lumen loss rate, 1-year patency rate of target vessel) in 1 year after the treatment will be compared.

femoropopliteal occlusive disease is a common type of peripheral arterial disease. endovascular treatment has been the first-line treatment of femoropopliteal occlusive disease. however, the in-stent re-stenosis has been a major limitation of well long-term patency rate after stent implantation. the chronic inflammation induced by stenting could be a main reason of re-stenosis. then the concept "leave nothing behind" is proposed, and some novel treatment methods and devices, such as paclitaxel-coated balloon dilation, directional atherectomy, are developed. directional atherectomy can effectively remove the atherosclerosis plaque but leave the inflammatory reaction along the atherectomy route. here, we propose the hypothesis that using local drug delivery with balloon system can relieve the inflammation induced by atherectomy. therefore, 40 patients of femoropopliteal occlusive disease will be randomly allocated into the group "directional atherectomy+local drug delivery with balloon system" or "drug-coated balloon only". the 1-year patency rate, incidence of complications, imaging parameters will be compared between groups.

Eligibility criteria:
inclusion criteria: * age of 18-80 years old * patients of femoropopliteal occlusive disease (rutherford 2-4) * length of lesion ≤ 20cm * have signed the informed consent exclusion criteria: * serum cr \> 150 umol/l * patients with acute thrombosis * received endovascular treatment for femoropopliteal disease in recent 6 months * less than 1 run-off vessel * allergic to aspirin, heparin, clopidogrel, paclitaxel, contrast medium * pregnancy and lactation * relatively easy bleeding * malignancy or irreversible organ failure

Keywords: femoropopliteal occlusive disease directional atherectomy local drug delivery endovascular treatment